Effect of Pentoxifylline on Cognitive Impairment After Ischemic Stroke and Its Mechanism of Brain Electricity and Brain Metabolism

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

Pentoxifylline can improve cognitive impairment after ischemic stroke, possibly by improving the level of cerebral blood flow, affecting the content of blood oxygen and metabolic substances in the brain, and then playing a protective role in the transmission of nerve electrical signals, and ultimately improving cognitive function. The patients with cognitive impairment and non-dementia PSCIND after ischemic stroke were randomly divided into two groups. In addition to the basic drugs of ischemic stroke, the patients were given pentothemine sustained release tablets and blank control respectively to observe the effects of pentothemine on cognitive function and neuronal electrical signals in the patients with ischemic PSCIND. It is expected to explore the possible internal biological mechanism by using transcranial Doppler, oxygen-dependent functional magnetic resonance imaging and craniocerebral magnetic resonance pop analysis. Finally, statistical correlation analysis was used to elucidate the specific mechanism of pentoxifylline in improving cognitive function of non-dementia patients with cognitive impairment after ischemic stroke.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 80
Healthy Volunteers: f
View:

• Han Chinese, age 40-80 years old, male and female, right-handed;

• The diagnosis is consistent with the Expert Consensus on the Management of Cognitive Impairment after Stroke 2021;

• NIHSS score 1-15 points;

• Daily Living Ability Scale (ADL) ≥75 score;

• The Informed consent signed by the patient or his legal representative

Locations
Other Locations
China
BHan
RECRUITING
Shijiazhuang
Contact Information
Primary
Bing Han, Ph.D. degree
Hanbing1987@hebmu.edu.cn
13784333398
Backup
Jiaying Rong, master
rjy19982023@163.com
15241876265
Time Frame
Start Date: 2024-04-10
Estimated Completion Date: 2024-12-31
Participants
Target number of participants: 200
Treatments
Experimental: Pentoxifylline
Pentoxifylline
No_intervention: No intervention
No intervention
Related Therapeutic Areas
Sponsors
Leads: The First Hospital of Hebei Medical University

This content was sourced from clinicaltrials.gov